A case report and literature review of rare intracranial and extracranial dual-lesion diffuse large B-cell lymphoma with heterogeneous subtypes (GCB type + ABC type) [0.03%]
罕见颅内颅外双中心弥漫大B细胞淋巴瘤（GCB型+ABC型）并存的病例报告及文献复习
Yadong Liu,Xuejuan Duan,Jinlong Liu et al.
Yadong Liu et al.
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma in adults. According to the gene expression profile, it can be classified into germinal center B-cell (GCB) type and activated B-cell (ABC) type. Cases w...
Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report [0.03%]
免疫检查点抑制剂治疗肾细胞癌骨转移的病例报告
Dimitar Metodiev,Tsvetan Borisov,Pierre-Alexis Da Costa et al.
Dimitar Metodiev et al.
Background: The immune landscape of renal cell carcinoma (RCC) is a key determinant of response to immune checkpoint inhibitors (ICIs). Yet, direct comparisons of immune infiltrates across histologic subtypes and metastat...
Oropharyngeal cancer mortality in the United States, 1999-2023: a surveillance analysis using CDC WONDER [0.03%]
美国1999-2023年咽癌死亡率：使用CDC WONDER进行的监测分析
Weichen Deng,Liren Cao,Zhihai Li
Weichen Deng
Background: Oropharyngeal cancer (OPC) is a major head and neck cancer subtype with shifting U.S. epidemiology. We performed a surveillance-style analysis of OPC mortality trends and demographic/geographic disparities, 19...
Advances in ultrasound for preoperative molecular subtyping of malignant breast tumors [0.03%]
乳腺恶性肿瘤术前分子分型的超声波进展
Dao-Rong Hong,Chun-Yan Huang
Dao-Rong Hong
Breast cancer molecular subtyping (luminal A, luminal B, HER2-enriched, and triple-negative) guides systemic therapy selection and prognostication, yet is still determined primarily by invasive tissue sampling. Over the last decade, ultraso...
Case Report: hidradenocarcinoma presenting with lymph node metastasis: a diagnostic challenge and the pivotal role of morphology [0.03%]
病例报告：伴有淋巴结转移的顶泌汗腺癌的诊断难题及形态学的关键作用
Lun Li,Lidi Tian,Tao Wang
Lun Li
Hidradenocarcinoma (HAC) is a rare malignant sweat gland tumor. When presenting with lymph node metastasis and an occult primary lesion, diagnosis is often significantly delayed. We report a case of a 58-year-old man with right axillary lym...
Lin Zhou,Jiakang Jiang
Lin Zhou
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, prompting significant advancements in therapeutic and precision medicine. Recent innovations include antibody-drug conjugates (ADCs) such as TROP-2-targ...
Global disparities in access to diagnostics and therapies for advanced non-small cell lung cancer: from discovery to delivery - a review [0.03%]
从发现到治疗：晚期非小细胞肺癌的诊断和疗法全球可及性差距述评
Lea Ruge,Malte Verheyen,Felix John et al.
Lea Ruge et al.
Advanced non-small cell lung cancer (NSCLC) has undergone a profound transformation over the past two decades through the integration of molecular diagnostics, targeted therapies, and immunotherapy into clinical practice. Despite these adva...
Poorly differentiated thyroid carcinoma: a case report and literature review [0.03%]
分化型较差的甲状腺癌一例报道及文献复习
Dong Zeng,Rong Wang,Zhen Liu et al.
Dong Zeng et al.
Poorly differentiated thyroid carcinoma (PDTC) is a rare and highly malignant tumor. To date, there have been very few case reports on PTCD, so its treatment methods remain controversial and require more experience. The island-like, solid-l...
Tamoxifen-induced neutropenia and leukopenia in a breast cancer patient: a case report and literature review [0.03%]
他莫昔芬致乳腺癌患者中性粒细胞减少及白细胞减少1例及相关文献复习
Cheng Liu,Fadong Xu,Qinglai Liu
Cheng Liu
Background: Tamoxifen is a cornerstone of endocrine therapy for hormone receptor-positive breast cancer. While its common side effects are well-documented, severe hematological toxicities such as neutropenia and leukopeni...
Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs [0.03%]
PD-1/PD-L1抑制剂联合多靶点抗血管生成TKI治疗晚期或转移性NSCLC的疗效：基于随机对照试验的meta分析
Zeqi Tang,Xiaoming Zhang,Zhanqi Sun et al.
Zeqi Tang et al.
Background: The efficacy of combining programmed cell death protein-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors with multi-targeted anti-angiogenic tyrosine kinase inhibitors (TKIs) in advanced or metastatic non...